Sugi Predict

Sugi Predict / Compounds / SCHEMBL1077176

SCHEMBL1077176

SCHEMBL1077176

CC(=O)c1cccn1-c1c(C#N)c2ccccc2n1-c1ccc(O)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 1/20 0.38
▸ SRC P12931 1/20 0.38
▸ ALDH1A1 P00352 4/20 0.38
▸ LMNA P02545 4/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ GAA P10253 2/20 0.38
▸ HTT P42858 2/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ MAPT P10636 1/20 0.38
▸ NCOA3 Q9Y6Q9 1/20 0.38
▸ MAPK1 P28482 1/20 0.37
▸ STAT3 P40763 1/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ HPGD P15428 1/20 0.36
▸ GLA P06280 1/20 0.35
▸ USP14 P54578 2/20 0.35
▸ TDP1 Q9NUW8 1/20 0.34
▸ POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1076215 0.86 EGFR (0.34) EGFRSRCALDH1A1MEN1KMT2A
SCHEMBL1077453 0.85 ALDH1A1 (0.41) EGFRSRCALDH1A1LMNAMEN1
SCHEMBL1075953 0.82 ALDH1A1 (0.41) EGFRSRCALDH1A1LMNAMEN1
SCHEMBL1077002 0.81 ALDH1A1 (0.38) EGFRSRCALDH1A1LMNAMEN1
SCHEMBL1077195 0.80 EGFR (0.34) EGFRSRCALDH1A1LMNAMEN1
SCHEMBL1076907 0.78 ALDH1A1 (0.43) EGFRSRCALDH1A1LMNAMEN1
SCHEMBL1039962 0.77 KDM4E (0.48) EGFRSRCALDH1A1LMNAMEN1
SCHEMBL1077332 0.76 CYP11B2 (0.39) EGFRSRCALDH1A1LMNAMEN1
SCHEMBL1076313 0.74 KDM4E (0.46) EGFRSRCALDH1A1LMNAMEN1
SCHEMBL1077607 0.73 ALDH1A1 (0.39) EGFRSRCALDH1A1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2276732-B1 NOVEL ESTROGEN RECEPTOR LIGANDS KAROBIO AB (SE) 2015-05-20 — — EP claimed
US-8653072-B2 Estrogen receptor ligands KARO BIO AB (SE) 2014-02-18 — — US claimed
US-20130131061-A1 Novel Estrogen Receptor Ligands KARO BIO AB (SE) 2013-05-23 — — US claimed
US-8367665-B2 Estrogen receptor ligands KARO BIO AB (SE) 2013-02-05 — — US claimed
US-20110190294-A1 NOVEL ESTROGEN RECEPTOR LIGANDS OASMIA PHARMACEUTICAL AB (SE) 2011-08-04 — — US claimed
CN-102066323-A Novel estrogen receptor ligands KAROBIO AB 2011-05-18 — — CN claimed
EP-2276732-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-01-26 — — EP claimed
WO-2009127686-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2009-10-22 — — WO claimed
EP-3782616-B1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES UNIV CALIFORNIA (US) 2023-11-01 — — EP disclosed
US-11628146-B2 Estrogen receptor ligand treatment for neurodegenerative diseases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-04-18 — — US disclosed
EP-3782616-A1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES The Regents of The University of California (US) 2021-02-24 — — EP disclosed
US-20210008002-A1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-01-14 — — US disclosed
US-10758496-B2 Estrogen receptor ligand treatment for neurodegenerative diseases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-09-01 — — US disclosed
EP-3189026-B1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES UNIV CALIFORNIA (US) 2020-07-22 — — EP disclosed
WO-2016036721-A1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-03-10 — — WO disclosed
EP-2276732-B1 NOVEL ESTROGEN RECEPTOR LIGANDS KAROBIO AB (SE) 2015-05-20 — — EP disclosed
US-8653072-B2 Estrogen receptor ligands KARO BIO AB (SE) 2014-02-18 — — US disclosed
US-20130131061-A1 Novel Estrogen Receptor Ligands KARO BIO AB (SE) 2013-05-23 — — US disclosed
US-8367665-B2 Estrogen receptor ligands KARO BIO AB (SE) 2013-02-05 — — US disclosed
US-20110190294-A1 NOVEL ESTROGEN RECEPTOR LIGANDS OASMIA PHARMACEUTICAL AB (SE) 2011-08-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210008002-A1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES ESR2, ESRRG, ESR1 EGFR 98/4885SRC 3222/4885ALDH1A1 2803/4885
US-11628146-B2 Estrogen receptor ligand treatment for neurodegenerative diseases ESR2, ESRRG, ESR1 EGFR 98/4885SRC 3222/4885ALDH1A1 2803/4885
US-20130131061-A1 Novel Estrogen Receptor Ligands ESR1, GPER1, ESRRA EGFR 65/4885SRC 1307/4885ALDH1A1 1765/4885
US-20110190294-A1 NOVEL ESTROGEN RECEPTOR LIGANDS ESR1, GPER1, ESRRA EGFR 69/4885SRC 1202/4885ALDH1A1 1909/4885
US-10758496-B2 Estrogen receptor ligand treatment for neurodegenerative diseases ESR2, ESRRG, ESR1 EGFR 98/4885SRC 3222/4885ALDH1A1 2803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.